Letter to the editor

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy

Supported by National Institutes of Health (NCCAM) grant R01-AT004435-04.

Disclosure of potential conflict of interest: M. Kulis has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) fellowship. J. A. Bird is a speaker for Nutricia and has received research support from the American Academy of Allergy, Asthma & Immunology (AAAAI)/Food Allergy Initiative (FAI) Howard Gittis Memorial Fellowship Award. B. P. Vickery has received research support from the NIH/NIAID and the Thrasher Research Fund. A. W. Burks is a minority stockholder in Allertein and Mast Cell, Inc; is on the advisory board for Dannon Co Probiotics; is a consultant for Exploramed Development LLC, Intelliject, McNeil Nutritionals, Merck, Novartis, Pfizer, Portola Pharmaceuticals Inv, and Schering-Plough; is on the Nutricia Expert Panel; has received research support from the NIH, Food Allergy and Anaphylaxis Network (FAAN), FAI, National Peanut Board, Scientific Hospital Supplies, and Wallace Research Foundation; has provided legal consultation/expert witness testimony on the topic of food allergy; is on the FAAN Medical Board of Directors; is an American College of Allergy, Asthma & Immunology Dermatological Allergy Committee Member; is an NIH/Human-Animal Interaction Study Section Member; and is on the Journal of Allergy and Clinical Immunology and US Food and Drug Administration Reviewer Boards. The rest of the authors declare that they have no relevant conflicts of interest.